Wafik El-Deiry on Muck Rack

Wafik El-Deiry

  • Translational Physician-Scientist and Contributor, Freelance
Pennsylvania
As seen in: LinkedIn, British Journal of Cancer, Nature, Journal of Banking Regulation, Educational Studies, MDPI, Molecular Cancer, Science Magazine, Cell Press, Healio and
Physician-Scientist tinyurl.com/s98xg3u Discoverer of p21(WAF1), TRAIL Death Receptor DR5 and TIC10/ONC201 the 1st ever FDA approval for H3K27M-gliomas
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Wafik

Contact Wafik, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms

|
By Charlotte Kuperwasser, Wafik El-Deiry
| Oncotarget
The COVID-19 pandemic and the widespread deployment of novel mRNA- and viral-vector based vaccines have reshaped the landscape of human immunology [1–4]. Never has such a large proportion of the global population been exposed simultaneously to nucleic acid–based immunogens, lipid nanoparticle (LNP) delivery systems, and repeated booster regimens over a relatively short period.
Open in Who Shared Issue with article?

Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure

|
By Shengliang Zhang, Wafik El-Deiry
| pubpeer.com
Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure Comment Oncotarget (2024) - pubmed: 38709242 doi: 10.18632/oncotarget.28582 issn: 1949-2553 Shengliang Zhang, Wafik S. El-Deiry
Open in Who Shared Issue with article?

Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death

|
By M. Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, John P. Plastaras, Jianhua Ling, Wenge Wang, Zhaoyu Jin, Yingqiu Liu, David T. Dicker, Paul Chiao, Keith T Flaherty, Charles Smith, Wafik El-Deiry
| Cell Press Verified
Main text (Cancer Cell 12, 66–80; July 2007) This publication demonstrated that cells expressing oncogenic are sensitized to TRAIL-induced apoptosis, and that the combination of TRAIL with sorafenib further enhances this sensitivity. We, the authors, were made aware of errors in the figures. The top panel (RelA/p65) in Figure 4E was duplicated from the top left panel (p65/RelA) in Figure 5H. Additionally, the IgG panel for Mcl-1 in Figure 4E was incorrectly placed.
Open in Who Shared Issue with article?
See all 76 licensed articles (79 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified